Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
combretastatin A4
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "combretastatin A4" in MCE Product Catalog:
4
Target:
2
2 Cited Publications
Cat. No.: HY-166648
DSPE-PEG2000-Maleimide sodium (purity>98%) is a functional lipid component and a thiol-reactive crosslinker. DSPE-PEG2000-Maleimide sodium (purity>98%) undergoes Michael addition with the thiol groups of thiolated or cyclic RGD peptides to form stable thioether bonds and DSPE-PEG2000-RGD. DSPE-PEG2000-Maleimide sodium (purity>98%) is applicable to research on drug delivery .
2
2 Cited Publications
Cat. No.: HY-166648A
DSPE-PEG-Maleimide ammonium (MW 2000) is a functional lipid component and a thiol-reactive crosslinker. DSPE-PEG-Maleimide ammonium (MW 2000) undergoes Michael addition with the thiol groups of thiolated or cyclic RGD peptides to form stable thioether bonds and DSPE-PEG (2000)-RGD. DSPE-PEG-Maleimide ammonium (MW 2000) is applicable to research on drug delivery .
Cat. No.: HY-17449
CAS No.: 168555-66-6
Synonyms: CA 4DP; CA 4P; combretastatin A4 disodium phosphate
Target:
Cat. No.: HY-N2146R
CAS No.: 117048-59-6
Synonyms: CRC 87-09 (Standard)
Category:
Cat. No.: HY-14815
CAS No.: 222030-63-9
Synonyms: combretastatin A4 phosphate
Target:
Research Areas:
Fosbretabulin (Combretastatin A4 phosphate) is a vascular disruptor with antitumor activity against atypical thyroid carcinoma (ATC) cell lines and xenografts. Fosbretabulin inhibits tumor growth by inhibiting microtubule polymerization, inducing apoptosis, and suppressing angiogenesis in tumors .
Cat. No.: HY-15855
CAS No.: 404886-32-4
Target:
Research Areas:
Fosbretabulin (tromethamine), also known as combretastatin A4 phosphate (CA4P), is a vascular disrupting agent evaluated for its efficacy against anaplastic thyroid carcinoma (ATC). It targets tumor neovasculature, causing acute and reversible reductions in tumor blood flow and central necrosis .
Cat. No.: HY-146506
CAS No.: 1067880-31-2
Target:
Research Areas:
isoCA-4, a Combretastatin A4 derivative, is a tubulin polymerization inhibitor. isoCA-4 has anti-proliferative activities .
Cat. No.: HY-W007614
CAS No.: 351-54-2
Synonyms: 3-Fluoro-para-anisaldehyde
Cat. No.: HY-149021
CAS No.: 2481404-89-9
Target:
Research Areas:
Tubulin polymerization-IN-28 (compound-4) is a microtubule protein polymerization inhibitor with highly selective anticancer activity. Tubulin polymerization-IN-28 can be activated by NQO1 and effectively release combretastatin A-4 to kill tumor cells. Tubulin polymerization-IN-28 can induce cell apoptosis and be used in anti-cancer research .
Cat. No.: HY-W275793
CAS No.: 139-45-7
Synonyms: Glycerol tripropionate
Target:
Research Areas:
Tripropionin (Glycerol tripropionate) is a triglyceride that can be hydrolyzed by carboxylic esterase from carrots. Tripropionin can serve as the oil phase for constructing high-performance lipid nanoemulsion droplets, enabling efficient encapsulation of Combretastatin A4 (HY-N2146) to achieve its stable storage and controlled release .
Cat. No.: HY-184708
Research Areas:
Les-6666 is a β-tubulin inhibitor. Les-6666 exerts antiproliferative, pro-apoptotic, cell cycle arrest and migration-inhibitory effects, and suppresses DNA synthesis. Les-6666 can be used in the research of pancreatic cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
